Gene Biotherapeutics, Inc. (CRXM) Stock Analysis

Gene Biotherapeutics, Inc. (CRXM) Healthcare & Pipeline Overview

Gene Biotherapeutics, Inc. is a clinical-stage biotechnology company developing angiogenic gene therapy for cardiovascular conditions, primarily focusing on Generx for myocardial ischemia and severe angina. Headquartered in San Diego, the firm is advancing its lead candidate through Phase 3 trials, leveraging a strategic manufacturing partnership to address significant unmet medical needs in the US market.

What Is the Investment Thesis for CRXM?

Gene Biotherapeutics, Inc. presents a research-stage profile centered on its lead angiogenic gene therapy candidate, Generx, currently in Phase 3 clinical trials for myocardial ischemia and severe angina. The potential approval of Generx represents a significant value driver, addressing a substantial unmet medical need in advanced coronary artery disease. The company's strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies supports the scalability required for potential commercialization. Exploration into additional indications, such as other cardiovascular and cerebral ischemic conditions, offers further long-term growth potential. However, as a clinical-stage biotechnology company with a $0.00B market capitalization and no established revenue, the investment is highly speculative, contingent on successful clinical trial outcomes, regulatory approvals, and future funding. The high beta of 19.29 indicates significant volatility, characteristic of early-stage biopharmaceutical ventures. Investors should monitor clinical trial progress, regulatory milestones, and financing activities closely.

Based on FMP financials and quantitative analysis

CRXM Key Highlights

Generx, the company's lead angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials for myocardial ischemia and severe angina.

• Gene Biotherapeutics has established a manufacturing partnership with Fujifilm Diosynth Biotechnologies for the production of Generx during its Phase 3 evaluations.
• The company operates with a lean structure, managing 3 employees, focusing on specialized gene therapy development.
• Gene Biotherapeutics, Inc. has a market capitalization of $0.00B, reflecting its early-stage development and lack of commercialized products.
• The stock exhibits a high Beta of 19.29, indicating significant volatility relative to the broader market, typical for clinical-stage biotechnology firms.

Who Are CRXM's Competitors?

CRXM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRXM's Key Strengths?

Generx, a lead angiogenic gene therapy candidate, is in advanced Phase 3 clinical trials, indicating significant development progress.

• Strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies ensures production capabilities for Generx.
• Focus on high-unmet-need conditions like myocardial ischemia and severe angina, offering potential for significant impact.
• Exploration of Generx for broader cardiovascular and cerebral ischemic applications demonstrates pipeline potential.

What Are CRXM's Weaknesses?

Currently a clinical-stage company with no established products generating revenue.

• Small operational footprint with only 3 employees, potentially limiting breadth of R&D or commercialization efforts.
• High beta of 19.29 indicates extreme stock price volatility.
• Limited liquidity and higher volatility due to OTC Other listing.

What Could Drive CRXM Stock Higher?

CRXM catalyst: Successful completion and positive data readout from Generx's Phase 3 clinical trials for myocardial ischemia and severe angina.

• Submission of a Biologics License Application (BLA) or similar regulatory filing for Generx to the FDA.
• Announcement of regulatory approval for Generx in its initial target indications.
• Continued exploration and preclinical/clinical development of Generx for additional cardiovascular and cerebral ischemic applications.
• Leveraging the manufacturing partnership with Fujifilm Diosynth Biotechnologies to ensure readiness for potential commercialization.

What Are the Key Risks for CRXM?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Failure of Generx to meet primary or secondary endpoints in ongoing Phase 3 clinical trials, leading to non-approval.
• Significant delays in the regulatory approval process for Generx, impacting commercialization timelines and increasing costs.
• The company's current lack of revenue generation and reliance on external funding to support ongoing R&D and operational expenses.
• High stock price volatility and limited liquidity due to its OTC Other listing and small market capitalization.
• Intense competition from other biotechnology and pharmaceutical companies developing therapies for cardiovascular diseases.

What Are the Growth Opportunities for CRXM?

• Successful Regulatory Approval and Commercialization of Generx for Myocardial Ischemia and Severe Angina: The primary growth driver for Gene Biotherapeutics is the successful completion of Generx's Phase 3 clinical trials, followed by regulatory approval from agencies like the FDA, and subsequent commercial launch. The target patient population for severe, intractable angina is significant, representing a substantial unmet medical need where current treatments may be insufficient. A successful market entry could establish Generx as a novel therapeutic option, generating the company's first revenue streams and validating its gene therapy platform. The market for cardiovascular disease therapies is projected to be in the hundreds of billions, and even a small share of this highly specialized segment could represent substantial growth for a company of this size.
• Expansion of Generx into Other Cardiovascular Ischemia Indications: Beyond its current focus on myocardial ischemia and severe angina, Generx's angiogenic mechanism of action could potentially be applicable to other forms of cardiovascular ischemia. This includes conditions such as peripheral artery disease or other forms of heart failure where improved blood flow and angiogenesis could offer therapeutic benefits. Expanding the indications for Generx would broaden its addressable market significantly, leveraging the existing research and development investment. This strategy would involve additional clinical trials but could unlock multiple revenue streams from a single core asset, enhancing the long-term value proposition and market reach.
• Exploration of Generx for Cerebral Ischemia Applications: Gene Biotherapeutics is actively exploring Generx's potential for therapeutic applications related to ischemia affecting the cerebral systems. Conditions like ischemic stroke or chronic cerebral ischemia represent another large and underserved medical area where restoring blood flow and promoting angiogenesis could have profound impacts. Successfully demonstrating efficacy and safety in cerebral indications would open up an entirely new market segment for Generx, diversifying the company's therapeutic portfolio beyond cardiovascular diseases. This expansion would require dedicated preclinical and clinical development, but the potential market size for neurological disorders is immense, offering substantial long-term growth.
• Leveraging Strategic Manufacturing Partnership for Scalable Production: The established manufacturing partnership with Fujifilm Diosynth Biotechnologies for Generx production during Phase 3 trials is a critical growth enabler. This partnership ensures that Gene Biotherapeutics has access to the necessary infrastructure and expertise to scale up manufacturing efficiently upon potential regulatory approval. Reliable and cost-effective production is paramount for gene therapies, which are complex to manufacture. This collaboration mitigates significant operational risks and positions the company to meet anticipated commercial demand, allowing it to focus resources on clinical development and market access strategies rather than building out its own extensive manufacturing capabilities, thereby accelerating potential market penetration.
• Future Pipeline Development Beyond Generx: While Generx is the primary focus, Gene Biotherapeutics' designation as a clinical-development stage biotechnology company implies ongoing research capabilities. Developing additional gene therapy candidates, either through internal discovery or strategic partnerships, could provide future growth opportunities. A diversified pipeline would reduce reliance on a single asset, mitigate clinical trial risks, and allow the company to address a broader range of diseases. This strategy would involve significant R&D investment but could lead to a robust portfolio of innovative therapies over the long term, securing sustained growth beyond the initial success of Generx.

What Threats Does CRXM Face?

• Clinical trial failure or unexpected adverse events for Generx, leading to non-approval.
• Intense competition from other biotechnology and pharmaceutical companies developing cardiovascular therapies.
• Significant capital requirements for ongoing R&D and potential commercialization, necessitating future funding.
• Regulatory hurdles and delays in the approval process for novel gene therapies.
• Market acceptance challenges for a new gene therapy treatment, even if approved.

What Are CRXM's Competitive Advantages?

• Proprietary angiogenic gene therapy candidate, Generx, currently in advanced Phase 3 clinical trials.
• Specialized focus on gene therapy for cardiovascular and cerebral ischemia, addressing high unmet medical needs.
• Strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies, securing production capabilities.
• Potential first-in-class treatment for severe, intractable angina, if approved.
• Expertise in navigating complex clinical development and regulatory pathways for gene therapies.

What Does CRXM Do?

Gene Biotherapeutics, Inc. is a biotechnology company operating in the clinical development stage, dedicated to the research, development, and commercialization of angiogenic gene therapy treatments for various cardiovascular conditions across the United States. Founded in 2003, the company initially operated under the name Taxus Cardium Pharmaceuticals Group, Inc., before officially rebranding to Gene Biotherapeutics, Inc. in January 2018. Headquartered in San Diego, California, the company's core focus revolves around its primary investigational compound, Generx. This angiogenic gene therapy candidate is currently undergoing pivotal Phase 3 clinical trials, targeting individuals afflicted with myocardial ischemia and severe, intractable angina, conditions frequently stemming from advanced coronary artery disease. Generx represents a potential novel therapeutic approach for patients who often have limited treatment options. Beyond its primary indication, Gene Biotherapeutics is actively exploring the broader therapeutic potential of Generx for other applications related to ischemia, encompassing both the cardiovascular and cerebral systems, indicating a strategic vision for pipeline expansion. To ensure the robust production of its Generx angiogenic gene therapy during these critical Phase 3 evaluations, Gene Biotherapeutics has established a strategic manufacturing partnership with Fujifilm Diosynth Biotechnologies, a collaboration vital for scaling up production as the therapy progresses towards potential commercialization. With a lean operational structure, managing 3 employees, the company emphasizes specialized expertise in gene therapy development.

What Products and Services Does CRXM Offer?

• Develops angiogenic gene therapy treatments for cardiovascular conditions.
• Primary focus is on Generx, an investigational compound in Phase 3 clinical trials.
• Generx aims to treat myocardial ischemia and severe, intractable angina caused by advanced coronary artery disease.
• Explores Generx's potential for other ischemic applications in both cardiovascular and cerebral systems.
• Partners with Fujifilm Diosynth Biotechnologies for Generx manufacturing during clinical trials.
• Operates as a clinical-stage biotechnology company in the United States.

How Does CRXM Make Money?

• Currently, the company is in the clinical development stage and does not generate revenue from product sales.
• Future revenue generation is contingent upon successful completion of Generx's Phase 3 trials, regulatory approval, and commercialization.
• Potential future revenue streams would derive from sales of Generx for its approved indications.
• Exploration of additional indications for Generx could expand future revenue opportunities.
• Potential for licensing agreements or partnerships for Generx in specific markets or for certain indications.

What Industry Does CRXM Operate In?

Gene Biotherapeutics, Inc. operates within the highly specialized and innovative biotechnology industry, specifically focusing on gene therapy for cardiovascular conditions. The broader biotechnology sector is characterized by intense research and development, lengthy clinical trial processes, and significant regulatory hurdles, but also holds the promise of transformative medical breakthroughs. The market for cardiovascular treatments is vast, driven by an aging global population and increasing prevalence of conditions like coronary artery disease, myocardial ischemia, and angina. Gene therapy, a cutting-edge segment of biotechnology, aims to treat diseases by modifying or introducing genetic material into a patient's cells. While still an emerging field, gene therapy has seen increasing regulatory approvals and investor interest, particularly for conditions with limited existing treatments. Gene Biotherapeutics positions itself within this landscape by targeting severe, intractable angina with its Generx candidate, aiming to offer a novel angiogenic approach where traditional therapies may fall short. The company's clinical-stage status places it among numerous biotechs vying for market share through innovation, requiring substantial capital and successful trial outcomes to compete effectively against established pharmaceutical giants and other emerging gene therapy players.

Who Are CRXM's Key Customers?

• Currently, no direct customers as the company is pre-commercial.
• Future customers would primarily be healthcare providers and institutions (hospitals, clinics) prescribing Generx.
• Ultimately, the end-users are patients suffering from myocardial ischemia, severe angina, and potentially other cardiovascular or cerebral ischemic conditions.
• Regulatory bodies (e.g., FDA) are key stakeholders in the approval process.

Company Profile

Gene Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Christopher J. Reinhard. CRXM has traded publicly since 2000.

Return on equity for Gene Biotherapeutics, Inc. stands at 12.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.4%, showing how much profit it generates from its asset base. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.

Gene Biotherapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

CRXM Financials

CRXM Latest News

No recent news available for CRXM.

CRXM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources